Search research articles
Contact Us
Filters
Showing results (111-120 of 143) with videos related to
Page
of 15
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 26, 2020
Sustained Response After Remdesivir and Convalescent Plasma Therapy in a B-Cell-Depleted Patient With Protracted Coronavirus Disease 2019 (COVID-19)
Jakob Malsy, Luzia Veletzky, Janna Heide, et al.
BMC Cancer
|
June 4, 2020
Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO 0217)
Joseph Tintelnot, Eray Goekkurt, Mascha Binder, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 19, 2023
A post hoc analysis of the EPAZ trial: The role of geriatric variables in elderly soft tissue sarcoma patients on toxicity and outcome
Rainer Hamacher, Xiaofei Liu, Markus K Schuler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 26, 2020
Randomized Comparison of Pazopanib and Doxorubicin as First-Line Treatment in Patients With Metastatic Soft Tissue Sarcoma Age 60 Years or Older: Results of a German Intergroup Study
Viktor Grünwald, Annika Karch, Markus Schuler, et al.
Blood
|
September 15, 2022
Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation-positive hairy cell leukemia
Robert J Kreitman, Philippe Moreau, Farhad Ravandi, et al.
Oncology Research and Treatment
|
November 17, 2024
Palbociclib in Combination with either Aromatase Inhibitors or Fulvestrant for Patients with Advanced HR+/HER2- Breast Cancer in Germany: Final Results of the Phase 2 Multicohort INGE-B Trial
Manfred Welslau, Karin Potthoff, Matthias Zaiss, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 27, 2025
FOLFOXIRI/bevacizumab versus doublets/bevacizumab as initial therapy of unresectable liver-only, right-sided and/or RAS or BRAF mutated metastatic colorectal cancer: An individual patient data-based pooled analysis of randomized trials
Carlotta Antoniotti, Federica Marmorino, Daniele Rossini, et al.
Nature Medicine
|
October 18, 2025
Perioperative pembrolizumab, trastuzumab and FLOT in HER2-positive localized esophagogastric adenocarcinoma: a phase 2 trial
Alexander Stein, Eray Goekkurt, Salah-Eddin Al-Batran, et al.
JAMA Oncology
|
December 23, 2020
Efficacy of Pazopanib With or Without Gemcitabine in Patients With Anthracycline- and/or Ifosfamide-Refractory Soft Tissue Sarcoma: Final Results of the PAPAGEMO Phase 2 Randomized Clinical Trial
Hans-Joachim Schmoll, Lars H Lindner, Peter Reichardt, et al.
Oncotarget
|
November 10, 2018
Multi-omic based molecular profiling of advanced cancer identifies treatable targets and improves survival in individual patients
Alexandra Samsen, Silvia von der Heyde, Carsten Bokemeyer, et al.
Page
of 15
Search research articles
Search
Showing results (111-120 of 143) with videos related to
Sort By:
Page
of 15
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 26, 2020
Sustained Response After Remdesivir and Convalescent Plasma Therapy in a B-Cell-Depleted Patient With Protracted Coronavirus Disease 2019 (COVID-19)
Jakob Malsy, Luzia Veletzky, Janna Heide, et al.
BMC Cancer
|
June 4, 2020
Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO 0217)
Joseph Tintelnot, Eray Goekkurt, Mascha Binder, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 19, 2023
A post hoc analysis of the EPAZ trial: The role of geriatric variables in elderly soft tissue sarcoma patients on toxicity and outcome
Rainer Hamacher, Xiaofei Liu, Markus K Schuler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 26, 2020
Randomized Comparison of Pazopanib and Doxorubicin as First-Line Treatment in Patients With Metastatic Soft Tissue Sarcoma Age 60 Years or Older: Results of a German Intergroup Study
Viktor Grünwald, Annika Karch, Markus Schuler, et al.
Blood
|
September 15, 2022
Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation-positive hairy cell leukemia
Robert J Kreitman, Philippe Moreau, Farhad Ravandi, et al.
Oncology Research and Treatment
|
November 17, 2024
Palbociclib in Combination with either Aromatase Inhibitors or Fulvestrant for Patients with Advanced HR+/HER2- Breast Cancer in Germany: Final Results of the Phase 2 Multicohort INGE-B Trial
Manfred Welslau, Karin Potthoff, Matthias Zaiss, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 27, 2025
FOLFOXIRI/bevacizumab versus doublets/bevacizumab as initial therapy of unresectable liver-only, right-sided and/or RAS or BRAF mutated metastatic colorectal cancer: An individual patient data-based pooled analysis of randomized trials
Carlotta Antoniotti, Federica Marmorino, Daniele Rossini, et al.
Nature Medicine
|
October 18, 2025
Perioperative pembrolizumab, trastuzumab and FLOT in HER2-positive localized esophagogastric adenocarcinoma: a phase 2 trial
Alexander Stein, Eray Goekkurt, Salah-Eddin Al-Batran, et al.
JAMA Oncology
|
December 23, 2020
Efficacy of Pazopanib With or Without Gemcitabine in Patients With Anthracycline- and/or Ifosfamide-Refractory Soft Tissue Sarcoma: Final Results of the PAPAGEMO Phase 2 Randomized Clinical Trial
Hans-Joachim Schmoll, Lars H Lindner, Peter Reichardt, et al.
Oncotarget
|
November 10, 2018
Multi-omic based molecular profiling of advanced cancer identifies treatable targets and improves survival in individual patients
Alexandra Samsen, Silvia von der Heyde, Carsten Bokemeyer, et al.
Page
of 15